News

DENVER, Colo. – The International Association for the Study of Lung Cancer (IASLC) recognizes the U.S. Food and Drug Administration’s (FDA) approval for another lung cancer immunotherapy agent (the second in two weeks) as a positive sign in the rapidly advancing science of lung cancer treatment. The last week the FDA approved nivolumab (Opdivo) to treat patients with advanced (metastatic) non-squamous non-small cell lung cancer (NSCLC) whose disease progressed during or after platinum-based chemotherapy. This is an extended approval of the use for nivolumab, as it was approved in March 2015 for squamous NSCLC in the same setting.

DENVER, Colo. – The International Association for the Study of Lung Cancer (IASLC) says the move by the U.S. Food and Drug Administration (FDA) to grant accelerated approval for a cutting-edge lung cancer treatment is a positive step forward that may help many patients improve their survival.

September 2015 Newsletter

Wow. We just completed another amazing World Conference in Lung Cancer (WCLC), this time in Denver! The pace of progress in lung cancer is amazing, and the WCLC is again the place to hear about it.

DENVER, Colo. – Thousands gained new insights and hope from the four-day World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer (IASLC) in Denver, Colo. on Sept. 6-9, 2015. The conference is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 6,000 researchers, physicians and specialists from nearly 100 countries.

DENVER, Colo. – The International Association for the Study of Lung Cancer (IASLC) featured several scientific abstracts during the 16th World Conference on Lung Cancer (WCLC) press program. Below are links to the releases for each individual abstract.

DENVER, Colo. — Previously, researchers reporting on SQUIRE study results demonstrated that the addition of necitumamub to gemcitabine-cisplatin improved overall survival in patients with stage IV squamous non-small cell lung cancer (NSCLC). Following up on these findings, Dr. Fred R. Hirsch, Professor of Medicine and Pathology at the University of Colorado, today presented additional analysis of the relationship with epidermal growth factor receptor (EGFR) protein and EGFR gene copy number at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC) in Denver, Colo.

Pages